Form 4: Bolt Biotherapeutics Director Acquires Stock Options

Bolt Biotherapeutics Director Laura Berner acquired stock options for 5,000 shares of common stock.

Summary

• Laura Berner, a Director at Bolt Biotherapeutics, Inc., was granted stock options.
• The options are for 5,000 shares of common stock.
• The exercise price for these options is $4.43 per share.
• The options have an expiration date of June 9, 2036.
• Vesting is scheduled for June 9, 2027, or the day before the next annual stockholder meeting, contingent on continued service.
• The options will fully vest upon a change in control of the company.
• The transaction was reported on June 11, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director and does not contain new financial performance data or strategic shifts.

Positives

• Director Laura Berner has been granted stock options, aligning her interests with shareholders.
• The stock options provide a potential upside for the director if the company's stock price increases.
• The vesting schedule encourages continued service and commitment to the company.
• Full vesting upon a change in control offers an incentive during potential acquisition scenarios.

Negatives

• The filing does not disclose any negative financial or operational information.
• The grant of options is a standard compensation practice and not inherently negative.

Risks

• The value of the stock options is contingent on the future performance of Bolt Biotherapeutics' stock.
• If the company's stock price does not exceed the exercise price of $4.43, the options may not be exercised profitably.
• The vesting is subject to continued service, meaning the director could forfeit unvested options if employment ceases before the vesting date.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and potential change in control events. The options are exercisable until June 9, 2036.

Management Comments

• The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology sector, aimed at incentivizing leadership and aligning their financial interests with long-term company value creation. This aligns with industry trends for executive compensation.

Related Party Transactions

• The acquisition of stock options by Director Laura Berner is a related party transaction.

Stakeholder Impact

• Shareholders: The issuance of options dilutes existing share ownership slightly, but also aligns director incentives with shareholder value.
• Employees: May be indirectly impacted by the company's performance, which the director's incentives are tied to.
• Management: The director's compensation is structured to reward performance and long-term commitment.

Next Steps

• Laura Berner may exercise the stock options on or after the vesting dates, provided the stock price is favorable.
• The options will fully vest upon a change in control of Bolt Biotherapeutics, Inc.

Key Dates

Keywords

Bolt Biotherapeutics, BOLT, Form 4, Stock Options, Insider Trading, Beneficial Ownership, Laura Berner, Director Compensation, SEC Filing